218 GSK Annual Report 2012 Financial statements of GlaxoSmithKline plc prepared under UK GAAP Disclosure of information to auditors Directors statement of responsibilities in relation to the companys financial The Directors in ofce at the date of this Report have each confirmed that: statements s so far as he or she is aware, there is no relevant audit The Directors are responsible for preparing the parent company, information of which the companys auditors are unaware: and GlaxoSmithKline plc, financial statements and the Remuneration Report in accordance with applicable law and regulations.
s he or she has taken all the steps that he or she ought to have taken as a Director to make himself or herself aware of any Company law requires the Directors to prepare financial statements relevant audit information and to establish that the companys for each financial year.
Under that law the Directors have elected auditors are aware of that information.
to prepare the parent company financial statements in accordance with United Kingdom Accounting Standards and applicable law This conrmation is given and should be interpreted in accordance United Kingdom Generally Accepted Accounting Practice.
Under with the provisions of section 418 of the Companies Act 2006. company law the Directors must not approve the parent company Going concern basis financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company for that period.
After making enquiries, the Directors have a reasonable expectation that the company has adequate resources to continue in operational In preparing those financial statements, the Directors are existence for the foreseeable future.
For this reason, they continue to required to: adopt the going concern basis in preparing the financial statements.
s select suitable accounting policies and then apply them consistently: The UK Corporate Governance Code s make judgements and accounting estimates that are reasonable The Board considers that GlaxoSmithKline plc applies the principles and prudent: and provisions of the UK Corporate Governance Code maintained by the Financial Reporting Council, as described in the Corporate s state with regard to the parent company financial statements Governance section on pages 94 to 108, and has complied with its that applicable UK Accounting Standards have been followed, provisions.
As required by the Financial Services Authoritys Listing subject to any material departures disclosed and explained in Rules, the auditors have considered the Directors statement of the parent company financial statements.
compliance in relation to those points of the UK Corporate The Directors are responsible for keeping adequate accounting records Governance Code which are specified for their review.
that are sufficient to show and explain the companys transactions and disclose with reasonable accuracy at any time the financial position of Sir Christopher Gent the company and to enable them to ensure that the parent company Chairman financial statements and Remuneration Report comply with the 5 March 2013 Companies Act 2006.
They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The parent company financial statements for the year ended 31 December 2012, comprising the balance sheet for the year ended 31 December 2012 and supporting notes, are set out on pages 220 to 223 of this report.
The responsibilities of the auditors in relation to the parent company financial statements are set out in the Independent Auditors report on page 219.
The financial statements for the year ended 31 December 2012 are included in the Annual Report, which is published in hard-copy printed form and made available on our website.
The Directors are responsible for the maintenance and integrity of the Annual Report on our website in accordance with UK legislation governing the preparation and dissemination of financial statements.
Access to the website is available from outside the UK, where comparable legislation may be different.
The Strategic review and Financial review and risk sections of the Annual Report include a fair review of the development and performance of the business and the position of the company and the Group taken as a whole, together with a description of the principal risks and uncertainties that it faces.
2-54 Strategic review 55-86 Financial review & risk 87-136 Governance & remuneration 137-223 Financial statements 224-248 Investor information GSK Annual Report 2012 219 Independent Auditors report Opinion on other matters prescribed by the Independent Auditors report Companies Act 2006 to the members of GlaxoSmithKline plc In our opinion: We have audited the parent company financial statements of s the part of the Directors Remuneration Report to be audited has GlaxoSmithKline plc for the year ended 31 December 2012 which been properly prepared in accordance with the Companies Act comprise the Company balance sheet UK GAAP and the related 2006: and notes A-H.
The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom s the information given in the Directors Report for the financial year Accounting Standards United Kingdom Generally Accepted for which the parent company financial statements are prepared is Accounting Practice.
consistent with the parent company financial statements.
Respective responsibilities of directors and auditors Matters on which we are required to report As explained more fully in the Directors statement of responsibilities by exception set out on page 218, the directors are responsible for the We have nothing to report in respect of the following matters where preparation of the parent company financial statements and for the Companies Act 2006 requires us to report to you if, in our being satisfied that they give a true and fair view.
Our responsibility opinion: is to audit and express an opinion on the parent company financial statements in accordance with applicable law and International s adequate accounting records have not been kept by the parent Standards on Auditing UK and Ireland.
Those standards require company, or returns adequate for our audit have not been us to comply with the Auditing Practices Boards Ethical Standards received from branches not visited by us: or for Auditors.
s the parent company financial statements and the part of the This report, including the opinions, has been prepared for and only Directors Remuneration Report to be audited are not in for the companys members as a body in accordance with Chapter 3 agreement with the accounting records and returns: or of Part 16 of the Companies Act 2006 and for no other purpose.
s certain disclosures of directors remuneration specified by law We do not, in giving these opinions, accept or assume responsibility are not made: or for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly s we have not received all the information and explanations we agreed by our prior consent in writing.
Scope of the audit of the financial statements Other matters An audit involves obtaining evidence about the amounts and We have reported separately on the Group financial statements of disclosures in the financial statements sufficient to give reasonable GlaxoSmithKline plc for the year ended 31 December 2012. assurance that the financial statements are free from material The company has passed a resolution in accordance with section misstatement, whether caused by fraud or error.
This includes an 506 of the Companies Act 2006 that the senior statutory auditors assessment of: whether the accounting policies are appropriate name should not be stated.
to the parent companys circumstances and have been consistently applied and adequately disclosed: the reasonableness of significant accounting estimates made by the directors: and the overall presentation of the financial statements.
In addition, we read all  LLP the financial and non-financial information in the Annual Report Chartered Accountants and Statutory Auditors to identify material inconsistencies with the audited financial London statements.
If we become aware of any apparent material 5 March 2013 misstatements or inconsistencies we consider the implications for our report.
Opinion on financial statements In our opinion the parent company financial statements: s give a true and fair view of the state of the companys affairs as at 31 December 2012: s have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice: and s have been prepared in accordance with the requirements of the Companies Act 2006.
220 GSK Annual Report 2012 Financial statements of GlaxoSmithKline plc prepared under UK GAAP Company balance sheet UK GAAP at 31 December 2012 2012 2011 Notes m m Fixed assets investments D 19,689 19,680 Debtors E 7,872 3,870 Cash at bank 10 19 Current assets 7,882 3,889 Creditors: amounts due within one year F 406 481 Net current assets liabilities 7,476 3,408 Net assets 27,165 23,088 Capital and reserves Called up share capital G 1,349 1,387 Share premium account G 2,022 1,673 Other reserves H 1,393 1,339 Profit and loss account H 22,401 18,689 Equity shareholders funds 27,165 23,088 Approved by the Board on 5 March 2013 Sir Christopher Gent Chairman GlaxoSmithKline plc Registered number: 3888792 2-54 Strategic review 55-86 Financial review & risk 87-136 Governance & remuneration 137-223 Financial statements 224-248 Investor information GSK Annual Report 2012 221 Expenditure Notes to the company balance sheet UK GAAP Expenditure is recognised in respect of goods and services received when supplied in accordance with contractual terms.
Provision is made when an obligation exists for a future liability in respect of a A Presentation of the financial statements past event and where the amount of the obligation can be reliably Description of business estimated.
GlaxoSmithKline plc is the parent company of GSK, a major global Investments in subsidiary companies healthcare group which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical Investments in subsidiary companies are held at cost less any products, including vaccines, over-the-counter OTC medicines provision for impairment.
Impairment of investments Preparation of financial statements The carrying value of investments are reviewed for impairment when there is an indication that the investment might be impaired.
Any The financial statements, which are prepared on a going concern provision resulting from an impairment review is charged to the basis, are drawn up in accordance with UK Generally Accepted income statement in the year concerned.
Accounting Practice UK GAAP and with UK accounting presentation as at 31 December 2012, with comparative gures Share based payments as at 31 December 2011.
Where appropriate, comparative gures are reclassied to ensure a consistent presentation with The issuance by the company to its subsidiaries of a grant over the current year information.
companys options, represents additional capital contributions by the company in its subsidiaries.
An additional investment in subsidiaries As permitted by section 408 of the Companies Act 2006, the results in a corresponding increase in shareholders equity.
The profit and loss account of the company is not presented in this additional capital contribution is based on the fair value of the grant Annual Report.
issued, allocated over the underlying grants vesting period.
Accounting convention and standards Taxation The balance sheet has been prepared using the historical cost Current tax is provided at the amounts expected to be paid applying convention and complies with applicable UK accounting standards.
tax rates that have been enacted or substantially enacted by the Accounting principles and policies balance sheet date.
The preparation of the balance sheet in conformity with generally The company accounts for taxation which is deferred or accelerated accepted accounting principles requires management to make by reason of timing differences which have originated but not estimates and assumptions that affect the reported amounts of reversed by the balance sheet date.
Deferred tax assets are only assets and liabilities and disclosure of contingent assets and liabilities recognised to the extent that they are considered recoverable at the date of the balance sheet.
Actual amounts could differ from against future taxable profits.
Deferred tax is measured at the average tax rates that are The balance sheet has been prepared in accordance with the expected to apply in the periods in which the timing differences companys accounting policies approved by the Board and described are expected to reverse.
Deferred tax liabilities and assets are in Note B. not discounted.
Financial guarantees B Accounting policies Liabilities relating to guarantees issued by the company on behalf Foreign currency transactions of its subsidiaries are initially recognised at fair value and amortised Foreign currency transactions are recorded at the exchange rate over the life of the guarantee.
ruling on the date of transaction, or at the forward rate if hedged by a forward exchange contract.
Foreign currency assets and liabilities C Operating profit are translated at rates of exchange ruling at the balance sheet date, A fee of 10,132 2011 11,474 relating to the audit of the or at the forward rate.
company has been charged in operating profit.
Dividends paid and received Dividends paid and received are included in the accounts in the period in which the related dividends are actually paid or received.
222 GSK Annual Report 2012 Financial statements of GlaxoSmithKline plc prepared under UK GAAP Notes to the company balance sheet UK GAAP continued D Fixed assets investments 2012 2011 m m Shares in GlaxoSmithKline Services Unlimited 613 613 Shares in GlaxoSmithKline Holdings One Limited 18 18 Shares in GlaxoSmithKline Holdings Limited 17,888 17,888 Shares in GlaxoSmithKline Mercury Limited 33 33 18,552 18,552 Capital contribution relating to share based payments 1,137 1,128 19,689 19,680 E Debtors 2012 2011 m m Amounts due within one year: UK Corporation tax recoverable 206 227 Amounts owed by Group undertakings 7,319 3,236 7,525 3,463 Amounts due after more than one year: Amounts owed by Group undertakings 347 407 7,872 3,870 F Creditors 2012 2011 m m Amounts due within one year: Bank overdraft 10 9 Amounts owed to Group undertakings 4 Other creditors 396 468 406 481 The company has guaranteed debt issued by one of its subsidiary companies for which it receives an annual fee from the subsidiary.
In aggregate, the company has outstanding guarantees over $10 billion of debt instruments.
The amount due from the subsidiary companies in relation to these guarantee fees will be recovered over the life of the bonds and are disclosed within debtors see Note E. 2-54 Strategic review 55-86 Financial review & risk 87-136 Governance & remuneration 137-223 Financial statements 224-248 Investor information GSK Annual Report 2012 223 Notes to the company balance sheet UK GAAP continued G Share capital and share premium account Share Ordinary Shares of 25p each premium Number m m Share capital authorised At 31 December 2011 10,000,000,000 2,500 At 31 December 2012 10,000,000,000 2,500 Share capital issued and fully paid At 1 January 2011 5,670,458,177 1,418 1,428 Issued under employee share schemes 21,949,144 5 245 Share capital cancelled 142,204,223 36 At 31 December 2011 5,550,203,098 1,387 1,673 Issued under employee share schemes 28,045,821 7 349 Share capital cancelled 180,652,950 45 At 31 December 2012 5,397,595,969 1,349 2,022 31 December 31 December 2012 2011 000 000 Number of shares issuable under outstanding options 114,985 126,810 Number of unissued shares not under option 4,487,419 4,322,987 At 31 December 2012, of the issued share capital, 75,205,594 shares were held in the ESOP Trusts, 494,951,327 shares were held as Treasury shares and 4,827,439,048 shares were in free issue.
All issued shares are fully paid.
The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 42, Employee share schemes.
A total of 174 million shares were purchased by the company during 2012 at a cost of 2,493 million and 181 million shares were cancelled.
The company expects to make further share repurchases of 12 billion during 2013.
The exact amount and timing of further purchases and whether the shares will be held as Treasury shares or be cancelled will be determined by the company and is dependent on market conditions and other factors.
No shares were purchased in the period 1 January 2013 to 28 February 2013.
H Reserves Other profit and reserves loss account Total m m m At 1 January 2011 1,282 10,031 11,313 Profit attributable to shareholders 14,255 14,255 Dividends to shareholders 3,406 3,406 Shares purchased and cancelled or held as Treasury share 36 2,191 2,155 Capital contribution relating to share based payments 21 21 At 31 December 2011 1,339 18,689 20,028 Profit attributable to shareholders 10,019 10,019 Dividends to shareholders 3,814 3,814 Shares purchased and cancelled or held as Treasury share 45 2,493 2,448 Capital contribution relating to share based payments 9 9 At 31 December 2012 1,393 22,401 23,794 The profit of GlaxoSmithKline plc for the year was 10,019 million 2011 14,255 million, which after dividends of 3,814 million 2011 3,406 million, gave a retained profit of 6,205 million 2011 10,849 million.
After the cost of shares purchased and cancelled or held as Treasury shares of 2,493 million 2011 2,191, the profit and loss account reserve at 31 December 2012 stood at 22,401 million 2011 18,689 million, of which 4,096 million is unrealised 2011 4,096 million.
224 GSK Annual Report 2012 Product development pipeline 225 Products, competition and intellectual property 229 Investor Quarterly trend 232 Five year record 236 Share capital and share price 239 Dividends 240 information Annual General Meeting 2013 241 US law and regulation 242 Tax information for shareholders 243 Analysis of shareholdings 244 Shareholder services and contacts 245 Glossary of terms and index 247 Join the conversation In 2012 we improved and broadened our communications channels to inform and engage with our stakeholders.
Find out more by visiting our new website www.
com or follow us on twitter @GSK to join the conversation.
